What is Niazid?
Niazid belongs to a group of medicines called antiprotozoals. It is used to treat diarrhea that is caused by certain types of protozoa (tiny, one-celled animals).
Niazid is available only with your healthcare professional's prescription.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although this use is not included in product labeling, Niazid is used in certain patients with the following medical condition:
- Intestinal parasitic infections
Niazid indications
Diarrhea Caused by Giardia Lamblia or Cryptosporidium Parvum
Niazid for
Oral Suspension (patients 1 year of age and older) and Niazid Tablets (patients 12 years and older) are indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum.
Limitations Of Use
Niazid for
Oral Suspension and Niazid Tablets have not been shown to be effective for the treatment of diarrhea caused by Cryptosporidium parvum in HIV-infected or immunodeficient patients.
How should I use Niazid?
Use Niazid suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Take Niazid suspension with food.
- Shake well before using.
- Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
- If you miss a dose of Niazid suspension, take it as soon as possible. If it is almost time for the next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Niazid suspension.
Uses of Niazid in details
Use: Labeled Indications
Diarrhea, infectious: Treatment of diarrhea caused by Cryptosporidium parvum or Giardia lamblia
Off Label Uses
Clostridioides (formerly Clostridium) difficile infection
Current evidence from small, controlled trials regarding the use of Niazid in the management of C. difficile infection suggests that it may be comparable to the use of oral metronidazole or vancomycin. The Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology (SHEA) clinical practice guidelines for C. difficile infection state that Niazid is considered a probable effective alternative for primary C. difficile infection in adults without specific recommendations for use. Larger controlled trials are needed.
Cryptosporidiosis-associated diarrhea in HIV-infected patients
Based on the US Department of Health and Human Services (HHS) Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, Niazid may be considered as an alternative agent in the management of diarrhea caused by Cryptosporidium in HIV-infected patients (must be used in combination with optimized antiretroviral therapy (ART), electrolyte replacement, and symptomatic treatment and rehydration).
Niazid description
Niazid, also known by the brand name Niazid, is a synthetic nitrothiazolyl-salicylamide derivative and an anti-protozoal agent. It is approved for treatment of infectious diarrhea caused by Cryptosporidium parvum and Giardia lamblia in patients 1 year of age and older. Following oral administration it is rapidly hydrolyzed to its active metabolite, tizoxanide, which is 99% protein bound. Peak concentrations are observed 1–4 hours after administration. It is excreted in the urine, bile and feces. Untoward effects include abdominal pain, vomiting and diarrhea. [Wikipedia]
Niazid dosage
Niazid Dosage
Generic name: Niazid 500mg
Dosage form: tablet; powder, for oral suspension
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
2.1 Recommended Dosage and Important Administration Instructions
Important Administration Instructions for Pediatric Patients 11 years of Age or Younger:
Niazid tablets should not be administered to pediatric patients 11 years of age or younger because a single tablet contains a greater amount of Niazid than the recommended dosing in this pediatric age group.
Table 1. Recommended Dosage
| Age | Dosage | Duration |
| 1-3 years | 5 mL of Niazid for Oral suspension(100 mg Niazid) taken orally every 12 hours with food | |
| 4-11 years | 10 mL of Niazid for Oral Suspension(200 mg Niazid) taken orally every 12 hours with food | 3 Days |
| 12 years and older | One Niazid Tablet (500 mg Niazid) taken orally every 12 hours with food or 25 mL of Niazid for Oral Suspension (500 mg Niazid) taken orally every 12 hours with food |
2.2 Directions for Mixing Niazid for
Oral Suspension
Reconstitute Niazid for
Oral Suspension as follows:
- Measure 48 mL of water for preparation of the 100 mg/5 mL suspension
- Tap bottle until all powder flows freely.
- Add approximately one-half of the 48 mL of water required for reconstitution and shake vigorously to suspend powder.
- Add remainder of water and again shake vigorously
Keep container tightly closed, and shake the suspension well before each administration. The reconstituted suspension may be stored for 7 days at room temperature, after which any unused portion must be discarded.
More about Niazid (Niazid)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 0 Reviews - Add your own review/rating
Consumer resources
- Niazid
- Niazid suspension
- Niazid (Advanced Reading)
Professional resources
- Niazid (AHFS Monograph)
- Niazid (FDA)
Related treatment guides
- Ascariasis
- Giardiasis
- Dwarf Tapeworm Infection (Hymenolepis nana)
- Amebiasis
- Cryptosporidiosis
Niazid interactions
See also:
What other drugs will affect Niazid?
Tizoxanide is highly bound to plasma protein (>99.9%). Therefore, caution should be used when administering Niazid concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin). In vitro metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes. Although no drug-drug interaction studies have been conducted in vivo, it is expected that no significant interaction would occur when Niazid is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes.
Niazid side effects
See also:
What are the possible side effects of Niazid?
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of Niazid was evaluated in 2177 HIV-uninfected subjects 12 months of age and older who received Niazid Tablets or Niazid for
Oral Suspension at the recommended dose for at least three days. In pooled controlled clinical trials involving 536 HIV-uninfected subjects treated with Niazid Tablets or Niazid for
Oral Suspension, the most common adverse reactions were abdominal pain, headache, chromaturia and nausea ( > 2%).
Safety data were analyzed separately for 280 HIV-uninfected subjects ≥ 12 years of age receiving Niazid at the recommended dose for at least three days in 5 placebo-controlled clinical trials and for 256 HIV-uninfected subjects 1 through 11 years of age in 7 controlled clinical trials. There were no differences between the adverse reactions reported for Niazid-treated subjects based upon age.
Postmarketing Experience
The following adverse reactions have been identified during post approval use of Niazid. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following is a list of adverse reactions spontaneously reported with Niazid Tablets which were not included in clinical trial listings:
Gastrointestinal disorders: diarrhea, gastroesophageal reflux disease
Nervous System disorders: dizziness
Respiratory, thoracic and mediastinal disorders: dyspnea
Skin and subcutaneous tissue disorders: rash, urticaria
Niazid contraindications
See also:
What is the most important information I should know about Niazid?
Hypersensitivity
Niazid Tablets and Niazid for
Oral Suspension are contraindicated in patients with a prior hypersensitivity to Niazid or any other ingredient in the formulations.
Active ingredient matches for Niazid:
Nitazoxanide in Bangladesh.
List of Niazid substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Netazox FC | |
| Netazox FC 500 mg Tablet (Ind-Swift Limited) | $ 0.09 |
| Nicud (Bangladesh) | |
| Nidozox (Bangladesh) | |
| Nit Clean (Egypt) | |
| Nitacol | |
| Nitacol 30 ml Suspension (Rexcel Pharmaceuticals Ltd) | $ 0.04 |
| Nitacure (India) | |
| Nitacure 200mg FC-TAB / 6 (Megacare (Alembic Chemical Works Co Ltd)) | $ 0.31 |
| Nitacure 500mg FC-TAB / 6 (Megacare (Alembic Chemical Works Co Ltd)) | $ 0.59 |
| 200 mg x 6's (Megacare (Alembic Chemical Works Co Ltd)) | $ 0.31 |
| 500 mg x 6's (Megacare (Alembic Chemical Works Co Ltd)) | $ 0.59 |
| Nitacure 30 ml Syrup (Megacare (Alembic Chemical Works Co Ltd)) | $ 0.05 |
| Nitacure 200 mg Tablet (Megacare (Alembic Chemical Works Co Ltd)) | $ 0.05 |
| Nitacure 500 mg Tablet (Megacare (Alembic Chemical Works Co Ltd)) | $ 0.09 |
| NITACURE film-coated tab 200 mg x 6's (Megacare (Alembic Chemical Works Co Ltd)) | $ 0.31 |
| NITACURE film-coated tab 500 mg x 6's (Megacare (Alembic Chemical Works Co Ltd)) | $ 0.65 |
| NITACURE SYP (India) | |
| 100 mg x 30ml (Alembic) | $ 0.29 |
| Nitacure SYP 100mg DRY-SYR / 30ml (Alembic) | $ 0.29 |
| NITACURE SYP dry syr 100 mg x 5 mL x 30ml (Alembic) | $ 0.29 |
| Nitacure SYP 100mg DRY-SYR / 30ml (Alembic) | $ 0.29 |
| NITADOX (India) | |
| NITADOX tab 500 mg x 6's (Signova) | $ 0.54 |
| Nitahelmin (Colombia) | |
| Nitanid (Bangladesh, Ecuador) | |
| NITARID (India) | |
| NITARID Capsule/ Tablet / 500mg / 6 units (Cipla Limited) | $ 0.54 |
| NITARID Dispersible Tablet / 200mg / 6 units (Cipla Limited) | $ 0.39 |
| NITARID Liquid / 10gm per 30ml / 30ml units (Cipla Limited) | $ 0.24 |
| 200 mg x 6's (Cipla Limited) | $ 0.39 |
| 500 mg x 6's (Cipla Limited) | $ 0.54 |
| 30ml (Cipla Limited) | $ 0.24 |
| Nitarid 200mg DT-TAB / 6 (Cipla Limited) | $ 0.39 |
| Nitarid 500mg TAB / 6 (Cipla Limited) | $ 0.54 |
| Nitarid - DRY-SYR / 30ml (Cipla Limited) | $ 0.24 |
| Nitarid 500 mg Tablet (Cipla Limited) | $ 0.10 |
| Nitarid 30 ml Syrup (Cipla Limited) | $ 0.24 |
| NITARID 100 MG SYRUP 1 bottle / 30 ML syrup each (Cipla Limited) | $ 0.25 |
| NITARID 200 MG TABLET DT 1 strip / 6 tablet dts each (Cipla Limited) | $ 0.32 |
| NITARID dispertab 200 mg x 6's (Cipla Limited) | $ 0.39 |
| NITARID tab 500 mg x 6's (Cipla Limited) | $ 0.54 |
| NITARID dry syr 100 mg x 5 mL x 30ml (Cipla Limited) | $ 0.24 |
| Nitarid 200mg DT-TAB / 6 (Cipla Limited) | $ 0.39 |
| Nitarid 500mg TAB / 6 (Cipla Limited) | $ 0.54 |
| Nitarid - DRY-SYR / 30ml (Cipla Limited) | $ 0.24 |
| Nitarid 100mg Syrup (Cipla Limited) | $ 0.25 |
| Nitarid 200mg Tablet DT (Cipla Limited) | $ 0.05 |
See 375 substitutes for Niazid | |
References
- DailyMed. "NITAZOXANIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "NITAZOXANIDE". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "NITAZOXANIDE". http://www.drugbank.ca/drugs/DB00507 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Niazid are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Niazid. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
